ProCE Banner Activity

REFLECT: Phase III Noninferiority Study of the Multikinase Inhibitor Lenvatinib vs Sorafenib as First-line Therapy in Unresectable Hepatocellular Carcinoma

Slideset Download
Conference Coverage
Lenvatinib demonstrated noninferior OS, significantly increased PFS, TTP, and ORR vs sorafenib with expected safety profile.

Released: June 05, 2017

Expiration: June 04, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology